Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

Frank M. Sacks, Jean Lucien Rouleau, Lemuel A. Moye, Marc A. Pfeffer, J. Wayne Warnica, J. Malcolm O Arnold, David T. Nash, Lisa E. Brown, Francois Sestier, John Rutherford, Barry R. Davis, C. Morton Hawkins, Eugene Braunwald, CARE Investigators The CARE Investigators

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

CARE will determine whether 5 years of cholesterol-lowering therapy reduces recurrent coronary disease events in 4,159 patients who have had an AMI. The mean total cholesterol and LDL-C levels in CARE (209 and 139 mg/dl) are similar to the average levels for the US population. The results of CARE will have relevance to the treatment of the majority of patients with coronary disease who have average rather than elevated cholesterol levels.

Original languageEnglish (US)
Pages (from-to)621-623
Number of pages3
JournalThe American journal of cardiology
Volume75
Issue number8
DOIs
StatePublished - Mar 15 1995

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels'. Together they form a unique fingerprint.

  • Cite this

    Sacks, F. M., Rouleau, J. L., Moye, L. A., Pfeffer, M. A., Warnica, J. W., Arnold, J. M. O., Nash, D. T., Brown, L. E., Sestier, F., Rutherford, J., Davis, B. R., Hawkins, C. M., Braunwald, E., & The CARE Investigators, CARE. I. (1995). Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. The American journal of cardiology, 75(8), 621-623. https://doi.org/10.1016/S0002-9149(99)80631-6